Skip to main content

Advertisement

SpringerLink
Log in

Tumor resensitization to erlotinib following brief substitution of cetuximab

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Targeted inhibition of epidermal growth factor receptors (EGFR) is becoming a standard anticancer treatment in defined clinical scenarios. EGFR inhibition may be achieved either by small-molecule orally bioavailable tyrosine kinase inhibitors, such as gefitinib or erlotinib, or else by large-molecule receptor antibodies, such as cetuximab or panitumumab. Here, we describe a case of pancreatic cancer in which the small-molecule EGFR antagonist erlotinib was used before and after the EGFR antibody cetuximab, with unexpected potentiation of both toxic and therapeutic sequelae.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Huang S, Armstrong EA, Benavente S et al (2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64:5355–5362

    Article  PubMed  CAS  Google Scholar 

  2. Matar P, Rojo F, Cassia R et al (2004) Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10:6487–6501

    Article  PubMed  CAS  Google Scholar 

  3. Fan Z, Lu Y, Wu X, Mendelsohn J (1994) Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269:27595–27602

    PubMed  CAS  Google Scholar 

  4. Jimeno A, Rubio-Viqueira B, Amador ML et al (2005) Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 65:3003–3010

    PubMed  CAS  Google Scholar 

  5. Perez-Soler R (2003) Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 17:23–28

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Haematology and Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Room 802, Administration Block, Pokfulam, Hong Kong, China

    R. J. Epstein

  2. Comprehensive Oncology Centre, Hong Kong Sanatorium and Hospital, Hong Kong, China

    R. J. Epstein & T. W. Leung

Authors
  1. R. J. Epstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. W. Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. J. Epstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Epstein, R.J., Leung, T.W. Tumor resensitization to erlotinib following brief substitution of cetuximab. Cancer Chemother Pharmacol 62, 1111–1112 (2008). https://doi.org/10.1007/s00280-008-0698-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0698-6

Keywords

Search

Navigation